SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist … Read more
SynAct Pharma AB (SYNACT) - Total Assets
Latest total assets as of September 2025: Skr253.58 Million SEK
Based on the latest financial reports, SynAct Pharma AB (SYNACT) holds total assets worth Skr253.58 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SynAct Pharma AB - Total Assets Trend (2014–2024)
This chart illustrates how SynAct Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SynAct Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
SynAct Pharma AB's total assets of Skr253.58 Million consist of 34.8% current assets and 65.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 22.6% |
| Accounts Receivable | Skr5.96 Million | 2.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr154.59 Million | 57.2% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how SynAct Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SynAct Pharma AB's current assets represent 34.8% of total assets in 2024, a decrease from 46.2% in 2014.
- Cash Position: Cash and equivalents constituted 22.6% of total assets in 2024, down from 35.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 54.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 57.2% of total assets.
SynAct Pharma AB Competitors by Total Assets
Key competitors of SynAct Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
SynAct Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SynAct Pharma AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SynAct Pharma AB is currently not profitable relative to its asset base.
SynAct Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 3.88 | 3.73 |
| Quick Ratio | 3.28 | 4.95 | 3.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr70.96 Million | Skr 47.18 Million | Skr 15.60 Million |
SynAct Pharma AB - Advanced Valuation Insights
This section examines the relationship between SynAct Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.10 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 18.6% |
| Total Assets | Skr270.52 Million |
| Market Capitalization | $50.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values SynAct Pharma AB's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SynAct Pharma AB's assets grew by 18.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SynAct Pharma AB (2014–2024)
The table below shows the annual total assets of SynAct Pharma AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr270.52 Million | +18.64% |
| 2023-12-31 | Skr228.02 Million | +59.91% |
| 2022-12-31 | Skr142.60 Million | +271.64% |
| 2021-12-31 | Skr38.37 Million | +77.69% |
| 2020-12-31 | Skr21.59 Million | -9.33% |
| 2019-12-31 | Skr23.81 Million | +69.75% |
| 2018-12-31 | Skr14.03 Million | -7.86% |
| 2017-12-31 | Skr15.23 Million | -50.20% |
| 2016-12-31 | Skr30.57 Million | +8008.83% |
| 2015-12-31 | Skr377.00K | -47.86% |
| 2014-12-31 | Skr723.00K | -- |